The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus
Adult
Male
Risk
0301 basic medicine
NCMLS 1: Infection and autoimmunity
NCMLS 1: Immunity, infection and tissue repair
N4i 1: Pathogenesis and modulation of inflammation
N4i 3: Poverty-related infectious diseases
Middle Aged
NCEBP 13: Infectious diseases and international health
3. Good health
Diabetes Complications
Interferon-gamma
03 medical and health sciences
N4i 2: Invasive mycoses and compromised host
Diabetes Mellitus, Type 2
Indonesia
Leukocytes, Mononuclear
Humans
Tuberculosis
UMCN 4.1: Microbial pathogenesis and host defense
Female
Disease Susceptibility
Cells, Cultured
DOI:
10.1007/s10096-007-0395-0
Publication Date:
2007-10-25T10:30:30Z
AUTHORS (9)
ABSTRACT
As patients with diabetes mellitus are at increased risk of developing tuberculosis, we hypothesized that this susceptibility to mycobacterial infection is due to a defective Th1-cytokine response. To explore this hypothesis, we examined four groups of subjects in Indonesia: 23 patients with tuberculosis, 34 patients with tuberculosis and diabetes, 32 patients with diabetes only and 36 healthy controls. Ex-vivo production of interferon (IFN)gamma, tumour necrosis factor-alpha and interleukin (IL)-1beta, 6, 10, -12 and -4 was measured following stimulation with Mycobacterium tuberculosis, Escherichia coli lipopolysaccharide and phytohaemagglutinin. Patients with active tuberculosis were found to have lower IFNgamma levels and a higher production of other pro-inflammatory cytokines and IL-4, both in the presence and absence of diabetes. Diabetes patients without tuberculosis, however, showed strongly reduced non-specific IFNgamma production, which is essential for inhibition of the initial growth of M. tuberculosis. Our data suggest that a defective non-specific immune response in diabetes may contribute to an increased susceptibility to develop tuberculosis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (32)
CITATIONS (104)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....